{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T04:08:56Z","timestamp":1750392536263,"version":"3.41.0"},"reference-count":9,"publisher":"American Society of Hematology","issue":"25","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6,19]]},"DOI":"10.1182\/blood.2025028710","type":"journal-article","created":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T15:31:29Z","timestamp":1750347089000},"page":"2936-2937","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["A natural head start to MRD negativity in multiple myeloma"],"prefix":"10.1182","volume":"145","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9709-7624","authenticated-orcid":false,"given":"Erin W.","family":"Meermeier","sequence":"first","affiliation":[{"name":"Mayo Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"25","key":"2025061911312062000_bib1","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1182\/blood.2024026455","article-title":"The bone marrow NK-cell profile predicts MRD negativity in patients with multiple myeloma treated with daratumumab-based therapy","volume":"145","author":"Korst","year":"2025","journal-title":"Blood"},{"issue":"4","key":"2025061911312062000_bib2","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N Engl J Med"},{"issue":"8","key":"2025061911312062000_bib3","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/S1470-2045(24)00282-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial","volume":"25","author":"Moreau","year":"2024","journal-title":"Lancet Oncol"},{"issue":"10","key":"2025061911312062000_bib4","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/S1470-2045(21)00428-9","article-title":"Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial","volume":"22","author":"Moreau","year":"2021","journal-title":"Lancet Oncol"},{"issue":"12","key":"2025061911312062000_bib11","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1038\/s43018-023-00657-1","article-title":"Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens","volume":"4","author":"Maura","year":"2023","journal-title":"Nat Cancer"},{"issue":"5","key":"2025061911312062000_bib6","doi-asserted-by":"crossref","first-page":"e881","DOI":"10.1097\/HS9.0000000000000881","article-title":"NK cell phenotype is associated with response and resistance to daratumumab in relapsed\/refractory multiple myeloma","volume":"7","author":"Verkleij","year":"2023","journal-title":"Hemasphere"},{"issue":"1","key":"2025061911312062000_bib7","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41408-024-01096-6","article-title":"Genomic and immune determinants of resistance to daratumumab-based therapy in relapsed refractory multiple myeloma","volume":"14","author":"Ziccheddu","year":"2024","journal-title":"Blood Cancer J"},{"issue":"12","key":"2025061911312062000_bib8","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1016\/j.immuni.2023.11.008","article-title":"Single-cell functional genomics reveals determinants of sensitivity and resistance to natural killer cells in blood cancers","volume":"56","author":"Dufva","year":"2023","journal-title":"Immunity"},{"issue":"1","key":"2025061911312062000_bib10","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41590-017-0006-x","article-title":"The twilight of immunity: emerging concepts in aging of the immune system","volume":"19","author":"Nikolich-\u017dugich","year":"2018","journal-title":"Nat Immunol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/25\/2936\/2380161\/blood_bld-2025-028710-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/25\/2936\/2380161\/blood_bld-2025-028710-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T15:31:30Z","timestamp":1750347090000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/145\/25\/2936\/537727\/A-natural-head-start-to-MRD-negativity-in-multiple"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,19]]},"references-count":9,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2025,6,19]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025028710","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6,19]]},"published":{"date-parts":[[2025,6,19]]}}}